# Ruxolitinib in Estrogen Receptor Positive Breast Cancer

> **NCT01594216** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 25 (actual)

## Conditions studied

- Estrogen-receptor Positive Invasive Metastatic Breast Cancer

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01594216
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594216, "Ruxolitinib in Estrogen Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01594216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*